Systematic Approach for the Diagnosis of IEM

유전성대사이상질환의 진단의 체계적 접근

  • 이홍진 (한림대학교 의과대학 소아청소년과학교실)
  • Published : 2014.12.25

Abstract

Recent advances in the diagnosis and treatment of inborn errors of metabolism (IEM) have improved substantially the prognosis of many of these diseases, if diagnosed early enough before irreversible damage occurs. Diseases of inborn errors of metabolism are so diverse over several hundred disease up to now and may be several thousand in near future, and these diversities of IEMs make clinicians embarassed. The signs of neurological dysfunctions of many IEMs manifesting in the neonatal period is very nonspecific, such as poor feeding, poor sucking, apnea or tachypnea, vomiting, hypertonia, hypotonia, seizure, letharginess, consciousness change and coma. But after neonatal period, the signs of neurological deficits become specific and localized. The results of routine basal laboratory tests such as metabolic acidosis, hyperammonemia, lactic acidemia, ketonemia or hyperuricemia can give very important clinical clues for the diagnosis of IEMs. Even no abnormal findings on routine laboratory test could be very important clue for NKH, sulfite oxidase deficiency and peroxisomal disorders. These various clinical manifestations of these diverse diseases can be categorized and summarized. This makes it essential that the practicing clinicians be familiar with the clinical presentations and symptomatic and systematic approaches of these disorders. Characteristic clinical presentations, methods of symptomatic and systematic approach and typing of various disorders is discussed in this review.

유전성대사장애질환의 진단과 치료는 최근들어 비약적인 발전을 하고 있으며, 치료가 불가능하여 대증적인 치료만이 가능하였던 많은 병들이 치료가 가능하 여지고 있다. 이러한 사실은 비가역적인 후유증이 생기기전의 조기진단의 중요성을 더 크게 한다. 유전성 대사장애질환은 현재 밝혀진 것만 하더라도 수백 가지의 질병에 이르며, 가까운 미래에 그 수는 수천에 이를 것으로 전망되고 있다. 이와 같은 질병의 다양성과 그 증상 및 임상적발현의 다양성은 임상의들이 정확한 진단에 이르는데 크나큰 장애요인이 되고 있다. 신생아기와 영아기 초기의 임상적인 발현은 비특이적이지만 나이가 들어가면서 다양한 특징적인 증상을 나타내게 된다. 같은 질병일지라도 잔류효소농도(residual enzyme activity)가 거의 없는 경우에는 신생아기 또는 영아기 등 이른시기에 증상이 나타나지만 잔류효소농도가 어느 정도 남아 있는 경우에는 늦게 소아기 또는 성인기에 증상을 나타내며, 유기산이나 지방산대사이상의 경우에는 이화작용이 증가되는 스트레스상태에서 갑작스런 악화를 보일 수도 있다. 본 논문에서는 이러한 다양한 증상과 검사소견들을 정리하여 보고, 그러한 증상을 일으키는 주된 질병들을 정리하여 감별진단과 검사를 체계적으로 접근할 수 있도록 하였다.

Keywords

References

  1. Hong Jin Lee. Systematic approach for the diagnosis of IEM in the neonatal period. J KSIMD 2014;14:10-18.
  2. Saudubray JM, Desguerre I, Sedel F, Charpentier C. A clinical approach to inherited metabolic disorders. In Fernandes J, Saudubray JM, van den Berghe G, Walter J, eds. Inborn metabolic Diseases: Diagnosis and Treatment, 4th edn. Berlin: Springer-Verlag, 2006.
  3. Burton BK. Nadler HL. Clinical diagnosis of inborn errors of metabolism in the neonatal period. Pediatrics 1978;61:398-405. https://doi.org/10.1542/peds.61.3.398
  4. Goodman SI. Inherited metabolic disease in the newborn: approach to diagnosis and treatment. Enzyme 1987;38:76-9. https://doi.org/10.1159/000469193
  5. Tada K, Kure S. Non-ketotic hyperglycinaemia: molecular lesion, diagnosis and pathophysiology. J Inherit Metab Dis 1993;16:691-703. https://doi.org/10.1007/BF00711901
  6. Chalmers PT, Lawson AH. Organic acids in man, Chapman and hall, 1982, Vol I.
  7. Nyhan WL. Multiple carboxylase deficiency. Int J Biochem 1988;20:363-70. https://doi.org/10.1016/0020-711X(88)90202-9
  8. Mahoney MJ. Organic acidemias. Clin Perinatol 1976;3:61-78.
  9. Desnick RJ, Brady R, Barranger J, et. al. Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy. Annals of Int Med 2003;138:338-347. https://doi.org/10.7326/0003-4819-138-4-200302180-00014
  10. Di mauro S, Bonilla E, Zeviani M, Servidei S, De Vivo DC, Schon EA. Mitochondrial myopathies. J Inherit Metab Dis 1987;10(suppl 1):113-28. https://doi.org/10.1007/BF01812852
  11. De Meirleir L. Disorders of pyruvate metabolism. Handb Clin Neurol 2013;113:1667-73. https://doi.org/10.1016/B978-0-444-59565-2.00034-4
  12. Lund AM, Skovby F, Vestergaard H, Christensen M, Christensen E. Clinical and biochemical monitoring of patients with fatty acid oxidation disorders. J Inherit Metab Dis 2010;33:495-500. https://doi.org/10.1007/s10545-009-9000-2
  13. Braverman NE1, D'Agostino MD, Maclean GE. Peroxisome biogenesis disorders: Biological, clinical and pathophysiological perspectives. Dev Disabil Res Rev 2013;17:187-96. https://doi.org/10.1002/ddrr.1113
  14. Hommes FA. Inborn errors of fructose metabolism. Am J Clin Nutr 1993;58(5 Suppl):788S-95S. https://doi.org/10.1093/ajcn/58.5.788S
  15. Kitagawa T. Hepatorenal tyrosinemia. Proc Jpn Acad Ser B Phys Biol Sci 2012;88:192-200. https://doi.org/10.2183/pjab.88.192
  16. Devictor D, Tissieres P, Afanetti M, Debray D. Acute liver failure in children. Clin Res Hepatol Gastroenterol 2011;35:430-7. https://doi.org/10.1016/j.clinre.2011.03.005